Press Releases March 5, 2024: MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial…MaaT PharmaMarch 5, 2024
Press Releases February 29, 2024: MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial…MaaT PharmaFebruary 29, 2024
Press Releases February 8, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…MaaT PharmaFebruary 8, 2024
Press Releases January 22, 2024: MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France,…MaaT PharmaJanuary 22, 2024
Press Releases January 8, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…MaaT PharmaJanuary 8, 2024
Press Releases December 12, 2023: MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations…MaaT PharmaDecember 12, 2023
Press Releases December 11, 2023: MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023 MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase…MaaT PharmaDecember 11, 2023
Press Releases December 5, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…MaaT PharmaDecember 5, 2023
Press Releases November 30, 2023: MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical…MaaT PharmaNovember 30, 2023
Press Releases November 13, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…MaaT PharmaNovember 13, 2023